Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study

ConclusionIn clinical practice, tolvaptan improved serum sodium and decreased hyponatremia symptoms in hyponatremia secondary to SIADH. Serum sodium should be monitored during treatment to minimize risk of rapid correction.Trial RegistrationClinicaltrials.gov identifier NCT01228682.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research